Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.
Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.
复制标题
DOI：
10.3390/ijms18030573
复制
发表时间：
2017-03-07
影响因子：
5.6
通讯作者：
Taguchi A
中科院分区：
文献类型：
--
作者：
Dayde D;Tanaka I;Jain R;Tai MC;Taguchi A
局部晚期直肠癌的标准治疗是新辅助放化疗（nCRT），然后进行根治性手术。患者对nCRT的反应各不相同，病理完全缓解与更好的结局相关。然而，缺乏有效的方法来选择从nCRT中获益或不获益的直肠癌患者。由于缺乏足够的敏感性和特异性，临床病理学和放射学特征的效用是有限的。分子生物标志物具有在早期时间点预测对nCRT的反应的潜力，但目前尚未进入临床。整合不同类型的生物标志物，包括临床病理学和成像特征，识别与肿瘤生物学的机制联系，以及使用代表疾病异质性的样本进行严格验证，将允许开发一种灵敏且具有成本效益的分子生物标志物面板，用于直肠癌的精准医学。在这里，我们的目的是审查组织和血液为基础的分子生物标志物研究的最新进展，并说明其在预测直肠癌nCRT反应的潜力。
The standard of care in locally advanced rectal cancer is neoadjuvant chemoradiation (nCRT) followed by radical surgery. Response to nCRT varies among patients and pathological complete response is associated with better outcome. However, there is a lack of effective methods to select rectal cancer patients who would or would not have a benefit from nCRT. The utility of clinicopathological and radiological features are limited due to lack of adequate sensitivity and specificity. Molecular biomarkers have the potential to predict response to nCRT at an early time point, but none have currently reached the clinic. Integration of diverse types of biomarkers including clinicopathological and imaging features, identification of mechanistic link to tumor biology, and rigorous validation using samples which represent disease heterogeneity, will allow to develop a sensitive and cost-effective molecular biomarker panel for precision medicine in rectal cancer. Here, we aim to review the recent advance in tissue- and blood-based molecular biomarker research and illustrate their potential in predicting nCRT response in rectal cancer.